SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Mometasone / Clotrimazole / Gentamicin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Veterinary product

1.3 Details of the supplier of the safety data sheet
   Company : MSD
             Kilshealan
             Clonmel Tipperary, IE
   Telephone : 353-51-601000
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Reproductive toxicity, Category 1A  H360D: May damage the unborn child.
   Short-term (acute) aquatic hazard, Category 1  H400: Very toxic to aquatic life.
   Long-term (chronic) aquatic hazard, Category 2  H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms : 
   Signal word : Danger
   Hazard statements : H360D  May damage the unborn child.
                      H410  Very toxic to aquatic life with long lasting effects.
   Precautionary statements : Prevention:
                             P201  Obtain special instructions before use.
Mometasone / Clotrimazole / Gentamicin Formulation

P273  Avoid release to the environment.
P280  Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313  IF exposed or concerned: Get medical advice/ attention.
P391  Collect spillage.

Storage:
P405  Store locked up.

Hazardous components which must be listed on the label:
Gentamicin

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>clotrimazole</td>
<td>23593-75-1</td>
<td>Acute Tox. 4; H302 Acute Tox. 3; H311 Eye Irrit. 2; H319 Repr. 2; H361fld STOT RE 2; H373 (Liver, Kidney, Adrenal gland) Aquatic Acute 1; H400 Aquatic Chronic 1; H410</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Index-No.</th>
<th>EC-No.</th>
<th>Registration number</th>
</tr>
</thead>
<tbody>
<tr>
<td>245-764-8</td>
<td>75-1</td>
<td></td>
</tr>
</tbody>
</table>
SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water.

For explanation of abbreviations see section 16.
Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed
Risks: May damage the unborn child.

4.3 Indication of any immediate medical attention and special treatment needed
Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media
Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

5.3 Advice for firefighters
Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
- See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
- If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe mist or vapours.
- Do not swallow.
- Avoid contact with eyes.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers:
- Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Organic peroxides
  - Explosives
  - Gases

7.3 Specific end use(s)

Specific use(s):
- No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

**Occupational Exposure Limits**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>White mineral oil</td>
<td>8042-47-5</td>
<td>OELV - 8 hrs (TWA) (inhalable fraction)</td>
<td>5 mg/m³</td>
<td>IE OEL</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>TWA</td>
<td>0.2 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Mometasone</td>
<td>83919-23-7</td>
<td>TWA</td>
<td>0.1 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Further information: Skin</td>
<td></td>
<td></td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>10 µg/100 cm²</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

**Engineering measures**
- All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
- Essentially no open handling permitted.
- Use closed processing systems or containment technologies.
If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

**Personal protective equipment**

**Eye protection**

- Wear safety glasses with side shields or goggles.
- If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
- Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Hand protection**

- Material: Chemical-resistant gloves
- Remarks: Consider double gloving.

**Skin and body protection**

- Material: Work uniform or laboratory coat.
- Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
- Use appropriate degowning techniques to remove potentially contaminated clothing.

**Respiratory protection**

- Material: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Equipment should conform to I.S. EN 14387

**Filter type**

- Combined particulates and organic vapour type (A-P)

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

- **Physical state**: suspension
- **Colour**: white to off-white
- **Odour**: oily
- **Odour Threshold**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flammability (solid, gas)**: Not applicable
- **Flammability (liquids)**: No data available
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
- **Flash point**: No data available
Mometasone / Clotrimazole / Gentamicin Formulation

Auto-ignition temperature: No data available
Decomposition temperature: No data available
pH: No data available
Viscosity: No data available
Viscosity, kinematic: No data available
Solubility(ies):
  Water solubility: No data available
Partition coefficient: n-octanol/water: Not applicable
Vapour pressure: No data available
Relative density: No data available
Density: No data available
Relative vapour density: No data available
Particle characteristics:
  Particle size: Not applicable

9.2 Other information
Explosives: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Evaporation rate: No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: None known.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents
10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Product:

Acute oral toxicity:
- Acute toxicity estimate: > 2,000 mg/kg
  Method: Calculation method

Acute dermal toxicity:
- Acute toxicity estimate: > 2,000 mg/kg
  Method: Calculation method

Components:

clotrimazole:

Acute oral toxicity:
- LD50 (Rat): 708 mg/kg
- LD50 (Mouse): 761 mg/kg
- LD50 (Rabbit): > 1,000 mg/kg

Acute inhalation toxicity:
- LC50 (Rat): > 0.73 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist

Gentamicin:

Acute oral toxicity:
- LD50 (Rat): 8,000 - 10,000 mg/kg
- LD50 (Mouse): 10,000 mg/kg

Acute inhalation toxicity:
- LC50 (Rat): > 0.2 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
  Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration):
- LD50 (Rat): 67 - 96 mg/kg
  Application Route: Intravenous
**Mometasone / Clotrimazole / Gentamicin Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.6</td>
<td>27.08.2021</td>
<td>415340-00017</td>
<td>09.04.2021</td>
</tr>
</tbody>
</table>

**LD50 (Rat): 371 - 384 mg/kg**
Application Route: Intramuscular

**LDLo (Monkey): 30 mg/kg**
Application Route: Intravenous

**Mometasone:**

<table>
<thead>
<tr>
<th>Acute oral toxicity</th>
<th>LD50 (Rat): &gt; 2,000 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LD50 (Mouse): &gt; 2,000 mg/kg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acute inhalation toxicity</th>
<th>LC50 (Rat): &gt; 3.3 mg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Exposure time: 4 h</td>
</tr>
<tr>
<td></td>
<td>Test atmosphere: dust/mist</td>
</tr>
<tr>
<td></td>
<td>Remarks: No mortality observed at this dose.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LC50 (Mouse): &gt; 3.2 mg/l</td>
</tr>
<tr>
<td></td>
<td>Exposure time: 4 h</td>
</tr>
<tr>
<td></td>
<td>Test atmosphere: dust/mist</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Acute toxicity (other routes of administration)</th>
<th>LD50 (Rat): 300 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Application Route: Subcutaneous</td>
</tr>
<tr>
<td></td>
<td>Symptoms: Breathing difficulties</td>
</tr>
</tbody>
</table>

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**clotrimazole:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>No skin irritation</td>
</tr>
</tbody>
</table>

**Gentamicin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Mild skin irritation</td>
</tr>
</tbody>
</table>

**Mometasone:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>No skin irritation</td>
</tr>
</tbody>
</table>

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

**clotrimazole:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rabbit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Result</td>
<td>Mild eye irritation</td>
</tr>
</tbody>
</table>
Gentamicin:
Species : Rabbit
Result : Mild eye irritation

Mometasone:
Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.
Respiratory sensitisation
Not classified based on available information.

Components:

Gentamicin:
Remarks : No data available

Mometasone:
Test Type : Maximisation Test
Exposure routes : Dermal
Species : Guinea pig
Assessment : Does not cause skin sensitisation.
Result : negative
Remarks : The results of a test on guinea pigs showed this substance to be a weak skin sensitisier.

Germ cell mutagenicity
Not classified based on available information.

Components:
clotrimazole:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
  Test Type: Chromosome aberration test in vitro
Result: negative
  Test Type: in vitro micronucleus test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Rat
Application Route: Oral
Result: negative

Test Type: Mammalian spermatogonial chromosome aberration test (in vivo)
Species: Hamster
Result: negative

Germ cell mutagenicity Assessment: Weight of evidence does not support classification as a germ cell mutagen.

**Gentamicin:**

Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Chromosome aberration test in vitro
Result: equivocal

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intravenous injection
Result: negative

**Mometasone:**

Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: positive

Test Type: Mouse Lymphoma
Result: negative

Genotoxicity in vivo: Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Test Type: Chromosomal aberration
Species: Rat
Cell type: Bone marrow
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone / Clotrimazole / Gentamicin Formulation

Version 4.6 Revision Date: 27.08.2021 SDS Number: 415340-00017 Date of last issue: 09.04.2021 Date of first issue: 14.12.2015

Result: negative

Germ cell mutagenicity - Assessment: Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

Components:

Clotrimazole:
- Species: Rat
- Application Route: Oral
- Exposure time: 78 weeks
- Result: negative

Gentamicin:
- Carcinogenicity - Assessment: No data available

Mometasone:
- Species: Rat
- Application Route: Inhalation
- Exposure time: 2 Years
- Dose: 0.067 mg/kg body weight
- Result: negative
- Species: Mouse
- Application Route: Inhalation
- Exposure time: 19 Months
- Dose: 0.160 mg/kg body weight
- Result: negative

Reproductive toxicity
May damage the unborn child.

Components:

Clotrimazole:
- Effects on fertility
  - Test Type: Fertility/early embryonic development
  - Species: Rat
  - Application Route: Oral
  - Fertility: LOAEL: 50 mg/kg body weight
  - Result: Effects on fertility

- Effects on foetal development
  - Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Oral
  - Developmental Toxicity: LOAEL: 100 mg/kg body weight
  - Result: Embryo-foetal toxicity, No teratogenic effects
  - Test Type: Embryo-foetal development
 Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 50 mg/kg body weight  
Result: Embryo-foetal toxicity, No teratogenic effects

Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 200 mg/kg body weight  
Result: No effects on foetal development

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 180 mg/kg body weight  
Result: No effects on foetal development

Reproductive toxicity - Assessment: Some evidence of adverse effects on sexual function and fertility, based on animal experiments. Some evidence of adverse effects on development, based on animal experiments.

Gentamicin:

Effects on fertility: Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Fertility: NOAEL: 20 mg/kg body weight  
Result: No significant adverse effects were reported

Effects on foetal development: Test Type: Embryo-foetal development  
Species: Rabbit  
Developmental Toxicity: NOAEL: 3.6 mg/kg body weight  
Result: No embryo-foetal toxicity

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 75 mg/kg body weight  
Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 10 mg/kg body weight  
Result: foetal mortality, No malformations were observed.

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 50 mg/kg body weight  
Result: foetal mortality, No malformations were observed.
Mometasone / Clotrimazole / Gentamicin Formulation

Mometasone:
Effects on fertility:
- Test Type: Fertility
- Species: Rat
- Application Route: Subcutaneous
- NOAEL: 0.015 mg/kg body weight
- Symptoms: Reduced embryonic survival, Reduced foetal weight
- Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal development:
- Test Type: Embryo-foetal development
  - Species: Mouse
  - Application Route: Subcutaneous
  - LOAEL: 0.06 mg/kg body weight
  - Result: Embryotoxic effects., Teratogenicity and developmental toxicity

- Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Dermal
  - LOAEL: 0.3 mg/kg body weight
  - Result: Embryo-foetal toxicity

- Test Type: Embryo-foetal development
  - Species: Rabbit
  - Application Route: Dermal
  - LOAEL: 0.15 mg/kg body weight
  - Result: Embryo-foetal toxicity, Malformations were observed.

- Test Type: Embryo-foetal development
  - Species: Rabbit
  - Application Route: Oral
  - LOAEL: 0.7 mg/kg body weight
  - Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment:
- Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure
- Not classified based on available information.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone / Clotrimazole / Gentamicin Formulation

Components:

Mometasone:
Remarks: Based on available data, the classification criteria are not met.

STOT - repeated exposure
Not classified based on available information.

Components:

Clotrimazole:
Target Organs: Liver, Kidney, Adrenal gland
Assessment: May cause damage to organs through prolonged or repeated exposure.

Gentamicin:
Target Organs: Kidney, inner ear
Assessment: Causes damage to organs through prolonged or repeated exposure.

Mometasone:
Exposure routes: inhalation (dust/mist/fume)
Target Organs: Immune system, Liver, Kidney, Skin
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Clotrimazole:
Species: Rabbit
LOAEL: 5 - 40 mg/kg
Application Route: Skin contact
Exposure time: 3 Weeks
Target Organs: Skin
Symptoms: Oedema, Fissuring, Necrosis, Redness

Species: Rat
LOAEL: 10 mg/kg
Application Route: Oral
Exposure time: 18 Months
Target Organs: Liver, Kidney, Adrenal gland

Species: Dog
LOAEL: 25 mg/kg
Application Route: Oral
Exposure time: 6 - 12 Months
Target Organs: Adrenal gland
Symptoms: Salivation, Lachrymation, Vomiting
Gentamicin:
Species : Dog
LOAEL : 3 mg/kg
Application Route : Intramuscular
Exposure time : 12 Months
Target Organs : Kidney
Symptoms : Vomiting, Salivation

Species : Monkey
LOAEL : 50 mg/kg
Application Route : Subcutaneous
Exposure time : 3 Weeks
Target Organs : Kidney, inner ear

Species : Monkey
LOAEL : 6 mg/kg
Application Route : Intramuscular
Exposure time : 3 Weeks
Target Organs : Blood, Kidney, inner ear, Liver

Species : Rat
NOAEL : 5 mg/kg
LOAEL : 10 mg/kg
Application Route : Intramuscular
Exposure time : 52 Weeks
Target Organs : Kidney, Blood

Species : Rat
NOAEL : 12.5 mg/kg
LOAEL : 50 mg/kg
Application Route : Intramuscular
Exposure time : 13 Weeks
Target Organs : Kidney

Mometasone:
Species : Rat
NOAEL : 0.005 mg/kg
LOAEL : 0.3 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat
NOAEL : 0.00013 mg/l
Mometasone / Clotrimazole / Gentamicin Formulation

Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species: Dog
NOAEL: 0.0005 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 90 d
Target Organs: Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity
Not classified based on available information.

Components:
Mometasone:
Not applicable

11.2 Information on other hazards

Endocrine disrupting properties

Product: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:
clotrimazole:
Skin contact: Symptoms: Rash, Itching, Blistering, Oedema, Redness
Ingestion: Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea

Gentamicin:
Ingestion: Target Organs: Kidney
Target Organs: inner ear
Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness

Mometasone:
Inhalation: Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact: Symptoms: Dermatitis, Itching
Further information

**Components:**

**Mometasone:**

Remarks: Dermal absorption possible

**SECTION 12: Ecological information**

**12.1 Toxicity**

**Components:**

**Clotrimazole:**

Toxicity to fish: LC50 (Brachydanio rerio (zebrafish)): > 0.29 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.02 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Desmodesmus subspicatus (green algae)): 0.268 mg/l
Exposure time: 72 h

NOEC (Desmodesmus subspicatus (green algae)): 0.017 mg/l
Exposure time: 72 h

M-Factor (Acute aquatic toxicity): 10

Toxicity to microorganisms: EC50: > 10,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity): NOEC: 0.025 mg/l
Exposure time: 32 d
Species: Oncorhynchus mykiss (rainbow trout)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC: 0.01 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity): 10

**Gentamicin:**

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 86 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
<table>
<thead>
<tr>
<th></th>
<th>LC50 (Americamysis): 30 mg/l</th>
<th>Exposure time: 96 h</th>
<th>Method: US-EPA OPPTS 850.1035</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Toxicity to algae/aquatic plants</strong></td>
<td>EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l</td>
<td>Exposure time: 72 h</td>
<td>Method: OECD Test Guideline 201</td>
</tr>
<tr>
<td></td>
<td>NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5 µg/l</td>
<td>Exposure time: 72 h</td>
<td>Method: OECD Test Guideline 201</td>
</tr>
<tr>
<td></td>
<td>EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 µg/l</td>
<td>Exposure time: 72 h</td>
<td>Method: OECD Test Guideline 201</td>
</tr>
<tr>
<td></td>
<td>NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l</td>
<td>Exposure time: 72 h</td>
<td>Method: OECD Test Guideline 201</td>
</tr>
<tr>
<td><strong>M-Factor (Acute aquatic toxicity)</strong></td>
<td>: 100</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Toxicity to microorganisms</strong></td>
<td>EC50 : 288.7 mg/l</td>
<td>Exposure time: 3 h</td>
<td>Test Type: Respiration inhibition</td>
</tr>
<tr>
<td><strong>M-Factor (Chronic aquatic toxicity)</strong></td>
<td>: 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mometasone:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Toxicity to fish</strong></td>
<td>LC50 (Menidia beryllina (Silverside)): 0.11 mg/l</td>
<td>Exposure time: 96 h</td>
<td>Remarks: No toxicity at the limit of solubility</td>
</tr>
<tr>
<td></td>
<td>LC50 (Cyprinodon variegatus (sheepshead minnow)): &gt; 5 mg/l</td>
<td>Exposure time: 7 d</td>
<td>Remarks: No toxicity at the limit of solubility</td>
</tr>
<tr>
<td><strong>Toxicity to daphnia and other aquatic invertebrates</strong></td>
<td>EC50 (Daphnia magna (Water flea)): &gt; 5 mg/l</td>
<td>Exposure time: 48 h</td>
<td>Method: OECD Test Guideline 202</td>
</tr>
<tr>
<td></td>
<td>EC50 (Americamysis): &gt; 5 mg/l</td>
<td>Exposure time: 96 h</td>
<td>Method: US-EPA OPPTS 850.1035</td>
</tr>
<tr>
<td><strong>Toxicity to algae/aquatic plants</strong></td>
<td>EC50 (Pseudokirchneriella subcapitata (green algae)): &gt; 3.2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone / Clotrimazole / Gentamicin Formulation

Version 4.6  Revision Date: 27.08.2021  SDS Number: 415340-00017  Date of last issue: 09.04.2021  Date of first issue: 14.12.2015

<table>
<thead>
<tr>
<th>Component</th>
<th>Toxicity to microorganisms</th>
<th>Toxicity to fish (Chronic toxicity)</th>
<th>Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)</th>
<th>M-Factor (Chronic aquatic toxicity)</th>
</tr>
</thead>
<tbody>
<tr>
<td>plants</td>
<td>EC50: &gt; 1,000 mg/l  Exposure time: 3 h  Test Type: Respiration inhibition  Method: OECD Test Guideline 209  Remarks: No toxicity at the limit of solubility</td>
<td>NOEC: 0.00014 mg/l  Exposure time: 32 d  Species: Pimephales promelas (fathead minnow)  Method: OECD Test Guideline 210</td>
<td>NOEC: 0.34 mg/l  Exposure time: 21 d  Species: Daphnia magna (Water flea)  Method: OECD Test Guideline 211  Remarks: No toxicity at the limit of solubility</td>
<td>100</td>
</tr>
</tbody>
</table>

12.2 Persistence and degradability

**Components:**

**Clotrimazole:**
- Stability in water: Hydrolysis: 50 % (242 d)

**Gentamicin:**
- Biodegradability: Result: rapidly degradable
- Biodegradation: 100 %  Exposure time: 28 d  Method: OECD Test Guideline 314

**Mometasone:**
- Biodegradability: Result: Not readily biodegradable
- Biodegradation: 50 %  Exposure time: 28 d  Method: OECD Test Guideline 314
- Stability in water: Hydrolysis: 50 % (12 d)  Method: OECD Test Guideline 111
12.3 Bioaccumulative potential

**Components:**

**Gentamicin:**
Partition coefficient: n-octanol/water : log Pow: < -2

**Mometasone:**
Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107.1
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

12.4 Mobility in soil

**Components:**

**Mometasone:**
Distribution among environmental compartments : log Koc: 4.02

12.5 Results of PBT and vPvB assessment

**Product:**
Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

**Product:**
Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product** : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in...
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

<table>
<thead>
<tr>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>UN 3082</td>
<td>UN 3082</td>
<td>UN 3082</td>
<td>UN 3082</td>
<td>UN 3082</td>
</tr>
</tbody>
</table>

14.2 UN proper shipping name

<table>
<thead>
<tr>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (clotrimazole, Gentamicin)</td>
<td>Environmentally hazardous substance, liquid, n.o.s. (clotrimazole, Gentamicin)</td>
</tr>
</tbody>
</table>

14.3 Transport hazard class(es)

<table>
<thead>
<tr>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
</tr>
</tbody>
</table>

14.4 Packing group

<table>
<thead>
<tr>
<th>ADN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Packing group: III</td>
</tr>
<tr>
<td>Classification Code: M6</td>
</tr>
<tr>
<td>Hazard Identification Number: 90</td>
</tr>
<tr>
<td>Labels: 9</td>
</tr>
<tr>
<td>ADR</td>
</tr>
</tbody>
</table>
Mometasone / Clotrimazole / Gentamicin Formulation

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID
Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

IMDG
Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)
Packing instruction (cargo aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

IATA (Passenger)
Packing instruction (passenger aircraft) : 964
Packing instruction (LQ) : Y964
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards

ADN
Environmentally hazardous : yes

ADR
Environmentally hazardous : yes

RID
Environmentally hazardous : yes

IMDG
Marine pollutant : yes

IATA (Passenger)
Environmentally hazardous : yes

IATA (Cargo)
Environmentally hazardous : yes

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone / Clotrimazole / Gentamicin Formulation

Version: 4.6  Revision Date: 27.08.2021  SDS Number: 415340-00017  Date of last issue: 09.04.2021
Date of first issue: 14.12.2015

Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII):
Number on list 3

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59):
Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer:
Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast):
Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals:
Not applicable

REACH - List of substances subject to authorisation (Annex XIV):
Not applicable

Number on list 3

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information:
Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements:
H302: Harmful if swallowed.
H311: Toxic in contact with skin.
Mometasone / Clotrimazole / Gentamicin Formulation

Version 4.6  Revision Date: 27.08.2021  SDS Number: 415340-00017

Date of last issue: 09.04.2021  Date of first issue: 14.12.2015

H319: Causes serious eye irritation.
H360D: May damage the unborn child.
H360Df: May damage the unborn child. Suspected of damaging fertility.
H361fd: Suspected of damaging fertility. Suspected of damaging the unborn child.
H372: Causes damage to organs through prolonged or repeated exposure if swallowed.
H373: May cause damage to organs through prolonged or repeated exposure if inhaled.
H373: May cause damage to organs through prolonged or repeated exposure if swallowed.
H400: Very toxic to aquatic life.
H410: Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations:

Acute Tox. : Acute toxicity
Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
Eye Irrit. : Eye irritation
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure
IE OEL : Ireland. List of Chemical Agents and Occupational Exposure Limit Values - Schedule 1
IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Re-
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Mometasone / Clotrimazole / Gentamicin Formulation

Version 4.6  Revision Date: 27.08.2021  SDS Number: 415340-00017  Date of last issue: 09.04.2021
Date of first issue: 14.12.2015


Classification of the mixture:
- Repr. 1A: H360D  Calculation method
- Aquatic Acute 1: H400  Calculation method
- Aquatic Chronic 2: H411  Calculation method

Classification procedure:
- Repr. 1A
- Aquatic Acute 1
- Aquatic Chronic 2

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN